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Abstract
To overview the present global burden of pneumococcal disease is important because new preventive measures such as the
pneumococcal conjugate vaccine 13 are currently being evaluated. Pneumococcal disease is roughly divided into non-invasive and
invasive disease. The burden of non-invasive pneumococcal disease in adults is mainly determined by community-acquired pneumonia.
Pneumococcal pneumonia has high incidence rates and carries a high mortality risk, especially in the elderly. Within the cluster of
invasive pneumococcal diseases, pneumonia also represents the most common infectious source. Incidence and mortality rates of
both non-invasive and invasive disease have changed as a result of pneumococcal vaccination in children. However, especially elderly
patients with comorbidities remain vulnerable to morbidity and mortality caused by pneumococcal disease. The current review
summarizes the current knowledge on the epidemiology including outcome of the main clinical forms of pneumococcal disease, with
a special focus on elderly patients. Furthermore, the economic burden and future vaccine strategies are brieﬂy discussed.
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Introduction
Pneumococcal disease (PD) can be divided into non-invasive
and invasive disease (Fig. 1) [1]. Considering the global
burden of PD is especially important, because new
preventive measures such as the pneumococcal conjugate
vaccine (PCV)13 are currently being evaluated. To assess
future effects, we aim to give an extensive overview of the
current burden of PD in adults. From that perspective,
incidence and mortality rates are described in pneumococcal
pneumonia (PP) and invasive pneumococcal disease (IPD).
Effects of the introduction of PCV7 vaccination in children
on these rates are also illustrated. Subsequently, because the
PD burden is especially high in the elderly, this age group
will be highlighted separately. Finally, the economic burden
of PD is described and future vaccine strategies are brieﬂy
discussed.
Non-invasive Pneumococcal Disease
Non-invasive PD can principally be divided into sinusitis, acute
otitis media and community-acquired pneumonia (CAP). As
the burden of disease in adults is mainly determined by CAP,
we will focus on CAP in this review.
FIG. 1. Classiﬁcation of pneumococcal disease [1].
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Aetiology of CAP
In daily practice, a microbiological diagnosis is made in only
about 20% of CAP. This can rise up to 60% when extensive and
costly diagnostic testing is performed [2].
Aetiological fractions of the most common pathogens in
CAP are summarized in Fig. 2 [3]. Accordingly, in a large
European review, Streptococcus pneumoniae was the most
frequently isolated pathogen in CAP (35% overall, ranging from
12 to 68% between various countries) [4]. This was true for all
settings, including outpatients, hospital-treated patients and
intensive care unit-treated patients [4]. Both European and
worldwide meta-analyses generally conﬁrmed these ﬁndings
and estimated the prevalence of S. pneumoniae in CAP to be
19.3% and 27.3%, respectively. [5, 6]. A recent study specif-
ically investigated CAP in outpatients and also found that
S. pneumoniae was the most frequent pathogen (35.1% of cases
with an established aetiological diagnosis) [7]. Similarly,
S. pneumoniae was the most frequent pathogen causing CAP
in younger patients (18–65 years) and patients with nursing-
home-acquired-pneumonia [8,9].
In conclusion, S. pneumoniae is the most important patho-
gen in CAP in various different settings, indicating that
epidemiological data on CAP in many cases mirror the
situation in PP.
Incidence of CAP
In Europe, incidence rates for CAP range from 1.6 per 1000 in
Spain to 11.6 per 1000 in Finland [10,11]. Reports from
England and Germany show intermediate rates (2.0 and 3.7–
10.1 per 1000, respectively) [12,13]. It is not known whether
these differences are related to study design or to actual
differences between populations. In the USA, incidence rates
for CAP requiring hospitalization were estimated to be 2.7 per
1000 in a large cohort [14]. Reliable data on incidence rates of
CAP in other parts of the world are scarce. The few studies
from the Asian-Paciﬁc region report incidence rates from 0.2
to 0.9 per 1000, but these are probably underestimated [15].
Some recently published studies report an increase of
hospital admissions due to CAP of about 30% in the last
decade, suggesting that the annual incidence rates might have
increased [12,16]. On the other hand, a study from the USA
presented opposing ﬁndings, with the number of CAP
hospitalizations declining by 54.8 per 100 000 annually after
the initiation of PCV7 vaccination, leading to 168 000 fewer
hospitalizations per year [17].
Outcome of CAP
In the USA, pneumonia was the eighth leading cause of death in
2004 and caused 1.3 million hospitalizations in 2005 [18].
Roughly, mortality rates can be divided into short-term
(in-hospital or 30-day mortality) and longer-term mortality.
Short-term mortality. Risk factors for short-term mortality in
CAP are shown in Table 1 [19–21]. In Europe, reported
short-term mortality of CAP varied between <1% and 48% [4].
This great variability depends on multiple factors, including
demographic differences, comorbid conditions, ambulatory
versus hospitalized patients and time to follow up.
The mean short-term mortality in CAPNETZ, a large
German competence network for CAP, was 8.6% (varying
from 0.8% in outpatients to 12.2% in hospitalized patients)
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FIG. 2. Mean aetiological fraction of community-acquired pneumonia
pathogens in adults admitted to the hospital. Abstracted and modiﬁed
from European Respiratory Society guidelines on lower respiratory
tract infections [3]. SP, Streptococcus pneumoniae; HI, Haemophilus
inﬂuenzae; LP, Legionella pneumophila; MC, Moraxella catarrhalis; SA,
Staphylococcus aureus; GNEB, Gram-negative enteric bacilli; PA,
Pseudomonas aeruginosa; MP, Mycoplasma pneumoniae; CS, Chlamydia
species (all); CPne, Chlamydophila pneumoniae; CPsi, Chlamydophila
psittaci; CB, Coxiella burnetii.
TABLE 1. Risk factors for short-term mortality in commu-
nity-acquired pneumonia (CAP) and invasive pneumococcal
disease [19–21].
Community-acquired pneumonia Invasive pneumococcal disease
Male gender Male gender
Neoplastic disease Solid malignancy
Neurological disease Increasing age
Bacteraemia Liver disease
Leucopenia Renal disease
Multilobar inﬁltrate Chronic pulmonary disease
Pleuritic chest pain Higher Charlson Index
Hypothermia Nursing home residence
Systolic hypotension High acute physiology score
Tachypnoea Mechanical ventilation
Diabetes mellitus Alcohol abuse
Smoking
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[22]. In Germany, overall in-hospital mortality for CAP was
14% in 2005–2006. Mortality started to increase signiﬁcantly
with age in patients older than 40 years. [23].
Examining in-hospital mortality differences between world
regions, the highest mortality was found in Latin America
(13.3%) followed by Europe (9.1%) and North America (7.3%)
[24].
Trends in in-hospital mortality between 1993 and 2005
were examined in the USA and decreased from 8.9% to 4.1%,
showing that mortality rates in CAP are changing [25].
Long-term mortality. The excess mortality after surviving the
initial CAP episode can be as high as 50% within 5 years [26]. A
Dutch cohort estimated cause-speciﬁc long-term mortality
(7 years) and found mortality rates more than three times as
high as in the general population. Malignancy (27%), chronic
obstructive pulmonary disease (19%) and cardiovascular dis-
ease (16%) were the most frequent causes of death [27].
Similarly, in a general practice population in the UK, 30-day and
3-year mortality in CAP patients were 18.5% and 30.8%,
respectively, versus 0.4% and 10.3% in controls [28].
Invasive Pneumococcal Disease
Invasive pneumococcal disease is deﬁned as an infection
conﬁrmed by the isolation of S. pneumoniae from a normally
sterile site, such as blood or cerebrospinal ﬂuid. The IPD
burden is mainly determined by pneumococcal meningitis,
bacteraemic PP and pneumococcal bacteraemia without a
primary focus.
In a description of almost 16 000 IPD cases in adults in the
USA, the origin of infection was pneumonia in 53% and
meningitis in 5%. In 40%, bacteraemia was diagnosed without a
focus [29].
Incidence of IPD
Invasive pneumococcal disease accounted for over 36 000
cases in the USA in 2011. The incidence of IPD was strongly
age-related with 38% of cases occurring in children under
2 years of age and another 54% in adults above 50 years of
age. IPD was more common in blacks than in whites (incidence
rates 16.6 vs 11.0/100 000) [30]. Incidence rates of IPD in
Europe ranged from 11 to 27 per 100 000, whereas estimates
from North America in the same period ranged from 15 to 49
per 100 000 [31–33]. Even higher incidence rates of IPD are
reported in particular regions of Asia, i.e. up to 216 cases per
100 000 annually in Taiwan [34]. Furthermore, numbers of IPD
in the developing world are probably underestimated because
of low diagnostic sensitivity and limited access to care.
Obviously, the incidence of IPD is inﬂuenced by preventive
measures such as vaccinations. PCVs have been developed
since the 1990s, and the use of PCV7 vaccination in children
was approved in 2000 by the US Food and Drug Administra-
tion and in 2001 by the European Union. Currently, 70% of
high-income countries are using PCV7 in their national
immunization programmes [35].
A large amount of data are available describing the impact of
PCV7 on IPD worldwide. A recent review, including ten
studies, showed a reduction in the post-vaccination incidence
rate of all serotype-IPD of 26.8% in comparison with the
pre-vaccination period. Highest reductions were seen in the
USA (44.7%) [36].
Of note, unvaccinated persons seem to be indirectly
protected from IPD, probably because of a reduction in
circulating infectious pathogens in the whole population, an
effect that is called ‘herd protection’ [37].
It is important that, in the above-mentioned review, two
European studies showed non-signiﬁcant increases in incidence
of IPD [36]. An additional European study also showed an
increase in overall IPD incidence from 14.2 to 17.9 cases per
100 000. Several mechanisms explaining these (geographical)
differences were proposed, including different vaccine cover-
age in the USA, ﬂuctuations in serotypes or outbreaks of
infections in speciﬁc areas [38].
Although overall IPD incidence after the introduction of
PCV7 decreased in the USA, the proportion of cases among a
speciﬁc population of high-risk adults (those with Pneumo-
coccal Polysaccharide Vaccine 23 indications) rose. In 1998,
51% of nearly 6000 IPD cases were among these adults,
whereas in 2009, this proportion rose to 61% of over 3000
cases, suggesting that despite the ‘herd protection’ these, often
elderly patients with comorbidities, remain a very susceptible
group for IPD [39].
Serotypes in IPD
Currently, at least 93 serotypes of pneumococci are known.
Serotypes are distinguished by their unique polysaccharide
capsule [40]. Before the introduction of PCV7, most pneumo-
coccal infections were caused by the seven serotypes in the
vaccine (4, 6B, 9V, 14, 18C, 19F and 23F). In adult and paediatric
studies from the USA in the late 1990s these serotypes
accounted for 59% and 87% of IPD, respectively [41].
After the introduction of PCV7, the serotype distribution
changed dramatically. A recent study from the USA showed
that PCV7-type IPD in all age groups decreased from 64% to
around 4% [42]. Similar observations were seen in Europe,
with, for example, one study from the UK showing a 98%
decrease in PCV7-type IPD in children younger than 2 years
and an 81% decrease in adults above 65 years [37].
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In the post-vaccine era, serotype 19A became the most
prevalent serotype (20% of isolates). However, after intro-
duction of PCV13 (PCV7 plus 1, 3, 5, 6A, 7F and 19A), no
further increase in prevalence was observed [42]. As expected,
even a reduction of 58% of serotype 19A isolates in young
children was observed after PCV13 introduction [43].
Outcome of IPD
Risk factors for short-term mortality in IPD are shown in
Table 1 [19–21]. Case mortality rates for IPD range from 11
to 30% in adults in the western world [31,44–46]. Recent
reports from Asia show case fatality rates of 26–30% [47,48].
The reported impact of PCV7 introduction on mortality rates
is variable. Studies from the USA generally show reductions in
mortality across all age groups, ranging from 38% to 78% [49–
51]. Another report from the USA found a decline of 18%
speciﬁcally in adults older than 50 years [52]. A recent study in
Europe on the other hand, presented unchanged case fatality
rates between periods from 1996 to 2001 and from 2005 to
2009 (15.2% vs 17.1%). IPD in the post-vaccine period was
even associated with higher rates of septic shock (19.1% vs
31.1%) and a trend towards higher case fatality in adults aged
between 50 and 65 years (11.6% vs 23.5%) [38].
Although paediatric vaccination programmes seem to
positively inﬂuence (especially vaccine-type) IPD incidence,
morbidity and mortality remain high.
Pneumococcal Disease in the Elderly
The human population is ageing, posing major challenges for
future health care [53]. Rates of PD have always been highest
among the very young and the very old [54]. In the elderly, PP
mainly determines the burden of PD. The presence of
underlying comorbid diseases, impaired mucociliary clearance
and a waning immune system all contribute to an increased risk
of (pneumococcal) pneumonia in the elderly [55].
As only a few studies have examined PP per se, most
conclusions can be drawn from reports about CAP in elderly
populations. Also in this elderly group, S. pneumoniae is the
most frequently isolated pathogen (40–50%) [56, 57].
The overall incidence of CAP rises dramatically with age,
with estimated rates ranging from 18.2 per 1000 person-years
in people aged 65–69 years, to as high as 52.3 per 1000
person-years in those aged over 85 years [58]. In a study from
Germany, overall incidence of CAP was 2.9 per 1000, rising up
to 7.7 in adults over 60 years and to 35.8 in adults over
90 years of age [23]. Furthermore, hospitalization rates for
elderly patients with pneumonia tend to increase, illustrated by
a 20% increase between 1988–1990 and 2000–2002 in the
USA [59]. Among US adults aged 50 years or older, nearly
30 000 cases of IPD and over 500 000 cases of non-bacterae-
mic PP were estimated to occur yearly, resulting in more than
25 000 pneumococcus-related deaths [60].
Mortality rates in the elderly with CAP are signiﬁcantly
higher than in CAP patients under 65 years, being 10.3%
versus 2.2% in a large Spanish cohort [61]. In elderly patients
with severe CAP requiring mechanical ventilation, mortality
rates rose as high as 55% [62].
Overall, it seems important to focus on preventive
measures against PD, especially in this group of vulnerable
elderly patients. Unfortunately, the changing immune system in
the elderly makes antibody responses weaker and protective
effects of vaccination are likely to be insufﬁcient precisely in
this group, which needs protection the most [63].
Economic Burden of Pneumococcal Disease
Pneumococcal disease carries a high economic burden. Direct
healthcare costs of PD totalled $3.5 billion in the USA in 2004.
PP accounted for 72% of these costs [64]. Therefore, it is
interesting to look into the more detailed data available about
costs for CAP. In Europe, total healthcare costs related to
CAP were estimated to be as high as €10.1 billion annually.
One-third is related to indirect costs, i.e. loss of working days
[65]. Furthermore, several studies measured hospitalization
costs for CAP in Europe. They were estimated to be between
€1201 and €2330 per episode [66–68]. One of these studies
speciﬁcally compared the costs of PP with non-PP, and found
that PP had signiﬁcantly higher overall costs (€2865 vs €2260,
respectively) [68]. Hospital costs in the USA are much higher
than in Europe. One review determined hospitalization costs
resulting from CAP to be $7000 to $8000 per episode [69].
Future costs for PD will probably rise, because the elderly
populationwill increaseworldwide. One study used an analytical
model to calculate future economic costsof PP in theUSA.These
costs will increase annually by $2.5 billion [70]. On the other
hand, possible future reductions in hospital stay could substan-
tially reduceCAP costs, with an approximate $2300 per reduced
day in the USA [71]. Furthermore, better preventive measures
will probably help to counteract the rise in costs for PD.
Impact of Novel Vaccines
Pneumococcal vaccination has seen important technical
developments within the last decade. Other articles in this
supplement cover pneumococcal vaccines in more detail. A
limitation of the polysaccharide vaccine is the limited
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protection against PP [72]. Because of the limited effective-
ness of polysaccharide vaccines in high-risk adults, at present
new conjugate vaccines (particularly PCV13) are being
evaluated for preventing PD in adults [73]. Previous experi-
ence in children and from immunological studies suggest
improved efﬁcacy [74,75]. Most is expected from a large
randomized trial in the Netherlands, establishing the pre-
ventive effect on PP of PCV13 in 85 000 adults over 65 years
of age [76]. Inclusion and follow up into this trial have been
completed and the ﬁrst results are expected early in 2014.
Many countries already changed their recommendations to
include conjugate vaccines [77].
Conclusion
Both non-invasive PD and IPD elicit a high medical and
economic burden. Elderly patients with comorbidities carry
the highest risk of developing PD.
In non-invasive PD, CAP carries the highest risk for
morbidity and mortality. Streptococcus pneumoniae remains
the most frequent pathogen in CAP and this is true for all
treatment settings. Pneumonia is also the most common
infectious source in adult IPD. The epidemiology of IPD
changed as the result of the introduction of paediatric PCV7
vaccination with a shift occurring towards serotypes not
included in the vaccine. Incidence rates of IPD generally
decreased, although a few studies showed (small) increases,
primarily in the elderly. Likewise, varying evidence is reported
about changes in IPD mortality after PCV7. Nevertheless, again
the vulnerable elderly remain exposed to a high risk of dying
because of IPD.
Hence, it is important to further develop and evaluate new
preventive measures.
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